Prostate specific membrane antigen based imaging

Abstract

Positron emission tomography-computed tomography (PET-CT) performed with new radiopharmaceuticals has revolutionized the imaging area in prostate cancer (Pca). 68Ga/18F-labeled prostate-specific membrane antigen (PSMA) has been the most promising radiotracer for staging and restaging of Pca. PSMA-based imaging outperformed conventional imaging (CI) in restaging and has a high clinical impact in patient management. Recently introduced 99mTc-labeled-PSMA compounds provide intraoperative guidance, which improved surgical outcomes of salvage surgical therapy. This chapter mainly focuses on PSMA-based imaging and discuss the potential benefits and limitations.